Gurjeet Singh1, Raksha Singh2, Anant Dattatraya Urhehar3. 1. Assistant Professor, Department of Microbiology, Dr. M.C. Saxena College of Medical Sciences , Lucknow, U.P, India . 2. Tutor, Department of Microbiology, MGM Medical College , Navi Mumbai, Maharashtra, India . 3. Professor and Head, Department of Microbiology, MGM Medical College , Navi Mumbai, Maharashtra, India .
Abstract
INTRODUCTION: Malaria is a human disease of which causes high morbidity and mortality. In Plasmodium falciparum malaria, the resistance to antimalarial drugs, especially chloroquine (CQ) is one of the paramount factors contributing to the global increase in morbidity and mortality, due to malaria. Hence, there is a need for detection of chloroquine drug resistance genes i.e., pfcrt-o (Plasmodium falciparum chloroquine resistance transporter-o) and pfmdr-1 (Plasmodium falciparum multidrug resistance-1) of P. falciparum and pvcrt-o (Plasmodium vivax chloroquine resistance transporter-o) and pvmdr-1 (Plasmodium vivax multidrug resistance-1) of P. vivax by using molecular methods to prevent mortality in malarial cases. AIM: To standardize chloroquine drug sensitivity testing by molecular method so as to provide reports of chloroquine within 6-8 hours to physicians for better treatment. MATERIALS AND METHODS: This study was conducted over a period of one year from January to December 2014. A Total of 300 blood samples were collected from malaria suspected patient attending MGM Hospital, Kamothe, Navi Mumbai, India. Out of 300 blood samples, 44 were malaria positive as assessed by Thick and Thin blood smear stained, by Leishman's method and examination with light microscope. Chloroquine drug sensitivity testing was performed using WHO III plate method (micro test). Nested PCR was done for detection of pfcrt-o and pfmdr-1 for P. falciparum and pvcrt-o, pvmdr-1 genes for P. vivax. RESULTS: Total 44 samples were included in this study, out of which 22 samples confirmed for Plasmodium falciparum and 22 samples confirmed for Plasmodium vivax. Out of 22 P. falciparum 15 (68.18%) samples were chloroquine resistant. P. vivax showed chloroquine resistance to 5 samples (22.73%) by method similar to WHO III plate method (micro test) and nested PCR. CONCLUSION: Drug resistance testing by molecular methods is useful for early detection of antimalarial drug resistance. pfmdr-1 along with pfcrt-o can be used as biomarker for chloroquine drug resistance in P. falciparum and pvmdr-1 along with pvcrt-o for P. vivax.
INTRODUCTION:Malaria is a human disease of which causes high morbidity and mortality. In Plasmodium falciparummalaria, the resistance to antimalarial drugs, especially chloroquine (CQ) is one of the paramount factors contributing to the global increase in morbidity and mortality, due to malaria. Hence, there is a need for detection of chloroquine drug resistance genes i.e., pfcrt-o (Plasmodium falciparumchloroquine resistance transporter-o) and pfmdr-1 (Plasmodium falciparum multidrug resistance-1) of P. falciparum and pvcrt-o (Plasmodium vivaxchloroquine resistance transporter-o) and pvmdr-1 (Plasmodium vivax multidrug resistance-1) of P. vivax by using molecular methods to prevent mortality in malarial cases. AIM: To standardize chloroquine drug sensitivity testing by molecular method so as to provide reports of chloroquine within 6-8 hours to physicians for better treatment. MATERIALS AND METHODS: This study was conducted over a period of one year from January to December 2014. A Total of 300 blood samples were collected from malaria suspected patient attending MGM Hospital, Kamothe, Navi Mumbai, India. Out of 300 blood samples, 44 were malaria positive as assessed by Thick and Thin blood smear stained, by Leishman's method and examination with light microscope. Chloroquine drug sensitivity testing was performed using WHO III plate method (micro test). Nested PCR was done for detection of pfcrt-o and pfmdr-1 for P. falciparum and pvcrt-o, pvmdr-1 genes for P. vivax. RESULTS: Total 44 samples were included in this study, out of which 22 samples confirmed for Plasmodium falciparum and 22 samples confirmed for Plasmodium vivax. Out of 22 P. falciparum 15 (68.18%) samples were chloroquine resistant. P. vivax showed chloroquine resistance to 5 samples (22.73%) by method similar to WHO III plate method (micro test) and nested PCR. CONCLUSION: Drug resistance testing by molecular methods is useful for early detection of antimalarial drug resistance. pfmdr-1 along with pfcrt-o can be used as biomarker for chloroquine drug resistance in P. falciparum and pvmdr-1 along with pvcrt-o for P. vivax.
Entities:
Keywords:
Drug resistant genes; Invitro antimalarial sensitivity; Nested PCR; Plasmodium species
Authors: Susan M Thomas; Omar Ndir; Therese Dieng; Souleymane Mboup; David Wypij; James H Maguire; Dyann F Wirth Journal: Am J Trop Med Hyg Date: 2002-05 Impact factor: 2.345
Authors: P G Vathsala; A Pramanik; S Dhanasekaran; C Usha Devi; C R Pillai; S K Subbarao; S K Ghosh; S N Tiwari; T S Sathyanarayan; P R Deshpande; G C Mishra; M R Ranjit; A P Dash; P N Rangarajan; G Padmanaban Journal: Am J Trop Med Hyg Date: 2004-03 Impact factor: 2.345
Authors: Wanna Chaijaroenkul; Stephen A Ward; Mathirut Mungthin; David Johnson; Andrew Owen; Patrick G Bray; Kesara Na-Bangchang Journal: Malar J Date: 2011-02-15 Impact factor: 2.979
Authors: Maria Isabel Veiga; Pedro Eduardo Ferreira; Louise Jörnhagen; Maja Malmberg; Aminatou Kone; Berit Aydin Schmidt; Max Petzold; Anders Björkman; Francois Nosten; Jose Pedro Gil Journal: PLoS One Date: 2011-05-25 Impact factor: 3.240
Authors: Gisely C Melo; Wuelton M Monteiro; André M Siqueira; Siuhelem R Silva; Belisa M L Magalhães; Aline C C Alencar; Andrea Kuehn; Hernando A del Portillo; Carmen Fernandez-Becerra; Marcus V G Lacerda Journal: PLoS One Date: 2014-08-26 Impact factor: 3.240
Authors: Rossarin Suwanarusk; Bruce Russell; Marina Chavchich; Ferryanto Chalfein; Enny Kenangalem; Varakorn Kosaisavee; Budi Prasetyorini; Kim A Piera; Marion Barends; Alan Brockman; Usa Lek-Uthai; Nicholas M Anstey; Emiliana Tjitra; François Nosten; Qin Cheng; Ric N Price Journal: PLoS One Date: 2007-10-31 Impact factor: 3.240